Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.

Cyrille Touzeau,Brigitte Kolb,Cyrille Hulin,Denis Caillot,Lotfi Benboubker,Mourad Tiab,Xavier Leleu,Murielle Roussel,Carine Chaleteix,Michel Attal,Thierry Facon,Philippe Moreau

Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.

2017

Cyrille Touzeau
Brigitte Kolb
Cyrille Hulin
Denis Caillot
Lotfi Benboubker
Mourad Tiab
Xavier Leleu
Murielle Roussel
Carine Chaleteix
Michel Attal
Thierry Facon
Philippe Moreau

8513 Background: MP+thalidomide (MPT) and MP+bortezomib (MPV) have shown significant progression-free survival and overall survival (OS) benefits in NDMM pts > 65 years (y) but are associated with ...

Keywords:

Pathology
Melphalan/prednisone
Thalidomide
Internal medicine
Oncology
Carfilzomib
Bortezomib
Medicine
Multiple myeloma
newly diagnosed
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations